F

Fulcrum Therapeutics
D

FULC

2.56000
USD
-0.07
(-2.66%)
مفتوح الان
حجم التداول
806
الربح لكل سهم
-1
العائد الربحي
-
P/E
-16
حجم السوق
138,187,023
أصول ذات صلة
E
ENJ
-1.270
(-5.95%)
20.080 USD
L
LINK
-0.25000
(-4.00%)
6.00000 USD
S
SAND
0.27000
(3.55%)
7.87000 USD
المزيد
الأخبار المقالات

العنوان: Fulcrum Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.